title: Itolizumab provides sustained remission in plaque psoriasis: a 5-year follow-up experience.
abstract: There is an unmet need for psoriasis therapies that provide long-term remission. Itolizumab is a humanized recombinant anti-CD6 monoclonal antibody shown to be effective in psoriasis. We report a patient who received itolizumab in a phase 2 clinical trial, and experienced long-term remission. At baseline, the patient's Psoriasis Area and Severity Index (PASI) was 12.2, and Physician's Global Assessment (PGA) score was 3. After 8 weeks of treatment, the patient achieved 97% improvement in PASI. She continued to have ≥ 90% improvement, initially for 4 weeks (follow-up phase), and later for 20 weeks (follow-up extension phase). She continued to visit the hospital after the final study visit; her most recent visit was on 10 May 2013. PGA results during the visits revealed sustained response for 4 years and 5 months after stopping itolizumab. Itolizumab could be therefore an important treatment option for moderate to severe psoriasis, with potential to provide long-lasting remission.
authors.affiliation: Department of Dermatology, Bowring and Lady Curzon Hospitals, Bangalore Medical College and Research Institute, Bangalore, India.
authors.forename: L
authors.initials: L
authors.lastname: Budamakuntla
authors.forename: M
authors.initials: M
authors.lastname: Madaiah
authors.forename: S
authors.initials: S
authors.lastname: Sarvajnamurthy
authors.forename: S
authors.initials: S
authors.lastname: Kapanigowda
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C000597346:itolizumab